Healthcare Industry News: bivalirudin
News Release - March 6, 2006
The Medicines Company Announces Glenn Sblendorio to Be New Chief Financial OfficerSteve Koehler to Depart as Chief Financial Officer on March 17, 2006
PARSIPPANY, N.J.--(HSMN NewsFeed)--March 6, 2006--The Medicines Company (NASDAQ: MDCO ) today announced that Glenn Sblendorio has joined the Company as an Executive Vice President and will become Chief Financial Officer effective March 17. Sblendorio replaces Steve Koehler, Senior Vice President and Chief Financial Officer who, after a very successful four years with the Company, has resigned effective March 17, to take a position with a large pharmaceutical company.
Glenn Sblendorio was formerly Executive Vice President and Chief Financial Officer at Eyetech Pharmaceuticals until it was acquired by OSI Pharmaceuticals in November of 2005. Prior to joining Eyetech, Glenn spent two years at The Medicines Company as Senior Vice President of Business Development. Glenn was also involved in the original start-up planning for the Company. Prior to joining The Medicines Company, Glenn was CEO and Managing Director at MPM Capital Advisors, and before then held Chief Financial Officer positions at Playnet Technologies Inc., Sony Interactive Entertainment Inc. and Roche Molecular Systems.
Clive Meanwell, Chairman and CEO of The Medicines Company stated, "Over the past four years, Steve Koehler has been a superb Chief Financial Officer. We thank him wholeheartedly for all of his important contributions and wish him well with his future. I anticipate a smooth transition between Steve and Glenn over the next few weeks. Glenn brings a wealth of leadership, financial and business transaction experience to the firm. We have worked together for many years, and I am delighted that Glenn has come back to lead both the financial and business development functions."
Mr. Sblendorio said, "In the last four years, The Medicines Company has emerged as an important player in acute hospital care, through well-developed commercial operations and product development expertise. I am fortunate to have the opportunity to re-join this special team at a time of great opportunity for the Company."
About The Medicines Company
The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax® (bivalirudin), an anti-clotting therapy approved in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators. The Company's website is http://www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, physicians' acceptance of Angiomax clinical trial results, whether the Company's products will advance in the clinical trials process, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approval for additional indications of Angiomax and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on November 8, 2005, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
Source: The Medicines Company
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.